Cancer Research

How Will AI Propel XCE853's Cancer Drug Development?
Research & Development How Will AI Propel XCE853's Cancer Drug Development?

In the evolving landscape of pharmaceuticals, the strategic partnership between Lantern Pharma and Oregon Therapeutics marks a significant milestone in the use of artificial intelligence (AI) for drug development. This collaboration centers on the advanced cancer drug candidate XCE853, an inhibitor

Is Lantern Pharma's LP-300 a New Hope for NSCLC Patients?
Management & Regulatory Is Lantern Pharma's LP-300 a New Hope for NSCLC Patients?

Lantern Pharma's LP-300 signals a significant advancement in the fight against non-small cell lung cancer (NSCLC), particularly in never-smokers—a group seeing elevated incidence rates, notably in East Asia. This promising therapeutic option stands out as NSCLC treatments often overlook the unique

New Genomic Study Sheds Light on Kidney Cancer Risk Factors
Research & Development New Genomic Study Sheds Light on Kidney Cancer Risk Factors

In a landmark multi-ancestry study by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), researchers have discovered 50 new genetic regions tied to the risk of kidney cancer. This extensive investigation involved a massive cohort comprising 29,020 kidney cancer

Is ALLO-316 the Future of Kidney Cancer Treatment?
Research & Development Is ALLO-316 the Future of Kidney Cancer Treatment?

In the fight against kidney cancer, ALLO-316, created by Allogene Therapeutics, stands out in the vanguard with its CAR T-cell therapy. This breakthrough offers new hope against renal cell carcinoma (RCC), a type notorious for its defiance against traditional treatments. As ALLO-316 progresses

Digital Health in Oncology: Transforming Cancer Care and Outcomes
Research & Development Digital Health in Oncology: Transforming Cancer Care and Outcomes

The integration of digital health into the field of oncology marks a pivotal shift in how cancer is managed and treated. This confluence of technology and healthcare has birthed new potentials in enhancing cancer prevention, diagnosis, treatment, and follow-up care. Digital health applications,

Can Utrophin Predict Tamoxifen Resistance in Breast Cancer?
Tech & Innovation Can Utrophin Predict Tamoxifen Resistance in Breast Cancer?

Breast cancer remains the most diagnosed cancer among women worldwide, posing significant challenges in terms of early detection, treatment efficacy, and overcoming drug resistance. Among the numerous hurdles faced by patients and oncologists alike is the phenomenon of tamoxifen resistance. As a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later